| Zeit | Aktuelle Nachrichten
Sprache: | Leser | Medien | |
|---|---|---|---|---|
| 20:19 | Lundbeck says drug shows improvement in depression symptoms | 1 | Reuters.com | |
| 19:57 | Lundbeck's Brintellix Is More Effective in Higher Dose in Study | 1 | Bloomberg | |
| 18:01 | H. Lundbeck A/S: Vortioxetine clinical phase III data show significant improvement in symptoms of major depression | 75 | GlobeNewswire | |
| Vortioxetine clinical phase III data show significant improvement in symptoms
of major depression
-- Takeda and Lundbeck present results from pivotal phase III clinical trials
with vortioxetine... Mehr lesen zu: H. Lundbeck A/S: Vortioxetine clinical phase III data show significant improvement in symptoms of major depression | ||||
| 18:01 | Takeda And Lundbeck Present Results From Pivotal Phase 3 Clinical Trials With Vortioxetine, An Investigational Compound For Major Depressive Disorder | 85 | PR Newswire | |
| SAN FRANCISCO, May 18, 2013 /PRNewswire/ --Takeda Pharmaceutical Company Limited (Takeda) and H. Lundbeck A/S (Lundbeck) today announced that the companies will be presenting new data from four studies... Mehr lesen zu: Takeda And Lundbeck Present Results From Pivotal Phase 3 Clinical Trials With Vortioxetine, An Investigational Compound For Major Depressive Disorder | ||||
| 16:19 | Lowest Return on Equity in the Biotechnology Industry Detected in Shares of Galectin Therapeutic | - | SmarTrend | |
| 15:49 | China Medicine has the Lowest Return on Equity in the Health Care Distributors Industry | - | SmarTrend | |
| 15:01 | Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AVEO Pharmaceuticals, Inc. To Contact The Firm | 82 | PR Newswire | |
| NEW YORK, May 18, 2013 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at AVEO Pharmaceuticals, Inc. ("AVEO" or the "Company")... Mehr lesen zu: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AVEO Pharmaceuticals, Inc. To Contact The Firm | ||||
| 15:01 | Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Ventrus Biosciences, Inc. To Contact The Firm | 70 | PR Newswire | |
| NEW YORK, May 18, 2013 /PRNewswire/ --Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Ventrus Biosciences, Inc. ("Ventrus" or the "Company")... Mehr lesen zu: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Ventrus Biosciences, Inc. To Contact The Firm | ||||
| 13:21 | Maximieren Sie Ihren Ertrag in nur 30 Minuten! (Freenet +370% / Technotrans +100% / Gilead +120% ...) | 315 | Der Aktionär | |
| Wenn man jemanden fragt, ob er einen Cappuccino trinken - oder zum gleichen Preis lieber einige Tausend Euro pro Jahr verdienen möchte, wird er sich vermutlich für den Zusatzverdienst entscheiden. Tatsächlich... Mehr lesen zu: Maximieren Sie Ihren Ertrag in nur 30 Minuten! (Freenet +370% / Technotrans +100% / Gilead +120% ...) | ||||
| 10:55 | Why MannKind's Afrezza Will Succeed Where Pfizer Failed | 8 | Seeking Alpha | |
| 03:01 | Ventrus Biosciences, Inc. Sued by Investor | 130 | PR Newswire | |
| SAN DIEGO andNEW YORK, May 17, 2013 /PRNewswire/ --Shareholder rights attorneys at Robbins Arroyo LLP announce that a shareholder of Ventrus Biosciences, Inc. (NASDAQ: VTUS) filed a federal securities... Mehr lesen zu: Ventrus Biosciences, Inc. Sued by Investor | ||||
| 01:36 | Abbott Laboratories Stock Checkup for May | 2 | Motley Fool | |
| 00:34 | Novartis Says BOLERO-3 Study On Afinitor Meets Main Goal | 161 | AFX News | |
| BASEL (dpa-AFX) - Novartis AG (NVS) said Friday that results of a pivotal
Phase III trial in women with HER2 positive advanced breast cancer showed that
Afinitor, or everolimus, tablets... Mehr lesen zu: Novartis Says BOLERO-3 Study On Afinitor Meets Main Goal | ||||
| 17.05. | PROGENICS PHARMACEUTICALS INC - 8-K, Current Report | - | SEC Filings | |
| 17.05. | Novartis International AG: Novartis drug Afinitor® significantly extended time without disease progression in women with HER2 positive advanced breast cancer | 140 | Thomson Reuters ONE | |
| Novartis International AG /
Novartis drug Afinitor® significantly extended time without disease progression
in women with HER2 positive advanced breast cancer
. Processed and transmitted by Thomson... Mehr lesen zu: Novartis International AG: Novartis drug Afinitor® significantly extended time without disease progression in women with HER2 positive advanced breast cancer | ||||
| 17.05. | Anthera Pharmaceuticals Inc - 8-K, Current Report | - | SEC Filings | |
| 17.05. | Alnylam to file rare disease drug application in 2014 | - | bizjournals | |
| 17.05. | Aeolus Strengthens Board of Directors With Oncology, Government Contracting and Financial Industry Veterans | 120 | Marketwired | |
| MISSION VIEJO, CA -- (Marketwired) -- 05/17/13 -- Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company leveraging significant government funding to develop a platform of novel compounds... Mehr lesen zu: Aeolus Strengthens Board of Directors With Oncology, Government Contracting and Financial Industry Veterans | ||||
| 17.05. | Durata Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | |
| 17.05. | Acura Pharmaceuticals Up 8.4%, Shares Break Through Resistance | 1 | SmarTrend | |
